Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04947137 · ClinicalTrials.gov registry record · Phase 2

Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept

A Phase 2 study, sponsored by Navidea Biopharmaceuticals.

Completed
Registry status
Phase 2
Development phase
134
Enrollment target

NCT04947137: Completed Phase 2 study, sponsored by Navidea Biopharmaceuticals.

NCT04947137 is a Phase 2 study that has completed, run by Navidea Biopharmaceuticals. The registered enrollment target is 134 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04947137, a Phase 2 study, has completed, sponsored by Navidea Biopharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
134 participants
Enrollment target

Study Summary

This study will establish a normative database of Tilmanocept Uptake Values (TUVjoint) in healthy controls age-matched to the RA population.

Primary Outcome

The normal limits of TUVjoint (on a per joint basis) in HC subjects, which are defined as the 5 and 95 percentiles of TUVjoint of bilateral joints (i.e., bilateral wrists, metacarpophalangeal joint \[MCPs\], proximal interphalangeal \[PIPs\]).

Interventions

  • DRUG Tc99m tilmanocept

Trial Details

FieldValue
Enrollment Target 134 participants
Start Date 2021-05-27
Est. Completion 2022-01-21
Phase Phase 2
Navidea Biopharmaceuticals

15 total trials

What the finished NCT04947137 record still lists

NCT04947137 is an interventional study that assigns participants to a tested intervention. The registered 134 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.

The record links to 0 conditions, and to 1 intervention - of which Tc99m tilmanocept is the first listed.

NCT04947137 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04947137 about?

NCT04947137 is a clinical study titled "Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept". This study will establish a normative database of Tilmanocept Uptake Values (TUVjoint) in healthy controls age-matched to the RA population.

What is the current status of trial NCT04947137?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 134 participants. The study started on 2021-05-27. Estimated completion is 2022-01-21.

What interventions are being tested in trial NCT04947137?

The interventions under investigation include: Tc99m tilmanocept (DRUG).

Who is sponsoring clinical trial NCT04947137?

This trial is sponsored by Navidea Biopharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04947137's enrollment target sits among peer trials

134 537th of 2000 higher than 1,463 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02469662 · 134 participants · NA

    Clinical Outcomes Study of the Nexel Total Elbow

  • NCT03110822 · 134 participants · Phase 1

    A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

  • NCT04678648 · 134 participants · Phase 1

    A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

  • NCT05264857 · 134 participants · NA

    Decision Aid and Thyroid Nodules Management

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04947137, the US trial registry maintained by the National Library of Medicine. NCT04947137 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.